Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S6 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study
  1. Home
  2. Publications
  3. Supplementary Table S6 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study

Supplementary Table S6 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study

Authors:
  • EYEvan Y. Yu
    Evan Y. Yu
  • VNVivek Narayan
    Vivek Narayan
  • GEGiuseppe Esposito
    Giuseppe Esposito
  • RSRussell Szmulewitz
    Russell Szmulewitz
  • YLYang Lu
    Yang Lu
  • MLMichael B. Lilly
    Michael B. Lilly
  • JCJeremie Calais
    Jeremie Calais
  • GBGennady Bratslavsky
    Gennady Bratslavsky
  • YMYusuf Menda
    Yusuf Menda
  • MVMinal Vasanawala
    Minal Vasanawala
  • FPFrédéric Pouliot
    Frédéric Pouliot
  • DLDavid Laidley
    David Laidley

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.32708693
Abstract
Subgroup Analyses of PSA50 Response
Keywords
  • RADIOLIGAND THERAPY
  • PROSTATE CANCER
  • SUPPLEMENTARY TABLE
  • STUDY SUBGROUP
  • SUBGROUP ANALYSES
  • PSMA-AVID METASTATIC
  • METASTATIC CASTRATION-RESISTANT
  • CASTRATION-RESISTANT PROSTATE
  • ENZALUTAMIDE VERSUS
  • VERSUS ENZALUTAMIDE
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.